Acute Hereditary Angioedema Treatment Agents

Acute hereditary angioedema treatment agents comprise a functional therapeutic class of medications indicated for the on-demand management and termination of acute attacks in patients with hereditary angioedema

Acute hereditary angioedema treatment agents comprise a functional therapeutic class of medications indicated for the on-demand management and termination of acute attacks in patients with hereditary angioedema The class includes plasma-derived or recombinant C1 esterase inhibitors that restore functional C1-INH regulatory activity, plasma kallikrein inhibitors that block the cleavage of high-molecular-weight kininogen, and competitive bradykinin B2 receptor antagonists that directly prevent bra...

Rather than sharing a single molecular structure, these agents target key nodes of the contact activation and kallikrein-kinin pathways to arrest excess bradykinin generation or activity, which drives localized vascular hyperpermeability and tissue edema

Rather than sharing a single molecular structure, these agents target key nodes of the contact activation and kallikrein-kinin pathways to arrest excess bradykinin generation or activity, which drives localized vascular hyperpermeability and tissue edema The class includes plasma-derived or recombinant C1 esterase inhibitors that restore functional C1-INH regulatory activity, plasma kallikrein inhibitors that block the cleavage of high-molecular-weight kininogen, and competitive bradykinin B2 re...

Their primary clinical role is to rapidly alleviate painful, debilitating subcutaneous or submucosal swelling episodes and avert fatal asphyxiation caused by acute laryngeal edema